This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Aegon ScotEq redress costs hit £171m

  • Print
  • Comments (3)

Aegon has revealed it has been hit by an additional £71m in costs associated with its Scottish Equitable redress programme, taking total redress costs to £171m.

In its latest quarterly results announced this morning, Aegon says it incurred further redress costs of £52m in the three months to the end of December with operating costs associated with making the redress payments of £19m.

The latest figures are on top of the £100m redress costs announced in November.

In December 2010, ScotEq’s UK life and pension business was fined £2.8m by the FSA and ordered to pay customers £60m following significant administrative failings.

Aegon’s results also reveal that its distribution arms, Positive Solutions and Origen, posted a combined loss of £2m for Q4 last year, following a loss of £1m for the previous quarter.

Over the year Pos Sol and Origen reported a £6m loss, compared to a £5m loss in 2010.

Total operating expenses for Aegon’s UK business were £98m, including the £19m costs associated with the ScotEq redress programme. Operating expenses also include charges of £42m related to Aegon’s restructuring programme, and £10m following the launch of Aegon’s white-labelled platform, powered by Novia. Aegon plans to launch a corporate platform, also backed by Novia, in June this year.

Aegon UK has posted a loss in pre-tax earnings for Q4 of £22m, compared to an £8m loss in Q3. For 2011 the company has posted a £5m pre-tax earnings profit, against a £61m profit in 2010.

Aegon has also announced that its UK chief executive Adrian Grace has been appointed to the company’s management board, subject to approval by the Dutch Central Bank. Grace was appointed chief executive in March 2011, previously having worked as chief operating officer since February 2010.

On the results Grace says: “Aegon UK successfully tackled some major historical issues in 2011 and this has had a negative financial impact in the short-term.

“Our 25 per cent cost saving target has been met and our customer redress programme is drawing to a close. Our platform proposition has been warmly received in the market. We are fully focused on the future and ensuring we take maximum advantage of the opportunities that lie ahead with the retail distribution review and pensions reform.

“Our development plans concentrate on our core markets of at retirement and workplace savings and we are on track to achieve our immediate and long-term goals.”

  • Print
  • Comments (3)

Daily Email Updates
If you enjoyed this article, sign up to receive the latest news and analysis from Money Marketing.

Money Marketing Awards 2015
Put your firm forward as the leading practitioner in your field. Adviser and Advertising categories are open to entries - Enter Now.

Readers' comments (3)

  • Paid from shareholder funds of course, will not affect policyholders in any way, and deliberated on by industry experts in the field?

    No complaints there then!

    Unsuitable or offensive? Report this comment

  • Not good news for one decent company.

    Unsuitable or offensive? Report this comment

  • As man on the moon says - a decent company, so it should be worrying that ScotEq is in loss making mode. The UK cannot afford the loss of any more insurance company capacity - we must must be verging on monopolistic conditions already. The loss of choice and competition would be worrying.
    From the information given it is important to ask whether the problem is caused or exacerbated by Regulatory requirements. If these are a material factors then they may also be a material factor to other insurance companies. Providing insurance, pension and investment products, and the advice associated with them is a commercial not a charitable process. Healthy competition is a normal assumption for a decent market. If the regulatory process is causing competition problems then it is imperative for the Director of Fair Trading to examine the market. That requirement is contained in the FSMA 2000.
    The cure should never be more deadly than the illness. The British public is entailed to be assured that this is not becoming the case before we have another RBS/HBOS scandal on our hands.

    Unsuitable or offensive? Report this comment

Have your sayEdit my profile/screen name

You must sign in to make a comment

Fund Data

Editor's Pick


How do you plan to vote at the general election?

Job of the week

Latest jobs

View all jobs

Most recent comments

View more comments